EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fortrea Holdings's enterprise value is €3,577 Mil.
Fortrea Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €98 Mil. Therefore, Fortrea Holdings's EV-to-EBITDA for today is 36.53.
The historical rank and industry rank for Fortrea Holdings's EV-to-EBITDA or its related term are showing as below:
FRA:K67'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.64 Med: 21.08 Max: 48.98
Current: 37.29
During the past 4 years, the highest EV-to-EBITDA of Fortrea Holdings was 48.98. The lowest was 13.64. And the median was 21.08.
FRA:K67's EV-to-EBITDA is ranked worse than 82.22% of 450
companies
in the Biotechnology industry
Industry Median: 9.57
vs FRA:K67: 37.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Fortrea Holdings EV-to-EBITDA Historical Data
The historical data trend for Fortrea Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fortrea Holdings's EV-to-EBITDA
For the Biotechnology subindustry, Fortrea Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortrea Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortrea Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Fortrea Holdings's EV-to-EBITDA falls into.
Fortrea Holdings's current Enterprise Value is €3,577 Mil.
Fortrea Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Fortrea Holdings's PE Ratio for today is calculated as:
Fortrea Holdings's share price for today is €23.00.
Fortrea Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.262.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Fortrea Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:K67 has been successfully added to your 